AU594014B2
(en)
*
|
1984-03-21 |
1990-03-01 |
Research Corporation Technologies, Inc. |
Recombinant DNA molecules
|
US5718893A
(en)
*
|
1984-04-15 |
1998-02-17 |
Foster; Preston F. |
Use of G-CSF to reduce acute rejection
|
DE3680613D1
(de)
*
|
1985-02-08 |
1991-09-05 |
Chugai Pharmaceutical Co Ltd |
Menschlicher granuloxcyt-kolonie-stimulierungsfaktor.
|
US5532341A
(en)
*
|
1985-03-28 |
1996-07-02 |
Sloan-Kettering Institute For Cancer Research |
Human pluripotent hematopoietic colony stimulating factor
|
US5078996A
(en)
*
|
1985-08-16 |
1992-01-07 |
Immunex Corporation |
Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor
|
US6004548A
(en)
*
|
1985-08-23 |
1999-12-21 |
Amgen, Inc. |
Analogs of pluripotent granulocyte colony-stimulating factor
|
US4810643A
(en)
*
|
1985-08-23 |
1989-03-07 |
Kirin- Amgen Inc. |
Production of pluripotent granulocyte colony-stimulating factor
|
NZ218336A
(en)
*
|
1985-12-09 |
1991-08-27 |
Kirin Amgen Inc |
Monoclonal antibodies to human pluripotent granulocyte colony stimulating factor (hpg-csf)
|
DK203187A
(da)
*
|
1986-04-22 |
1987-10-23 |
Immunex Corp |
Human g-csf proteinekspression
|
GR871067B
(en)
*
|
1986-07-18 |
1987-11-19 |
Chugai Pharmaceutical Co Ltd |
Process for producing stable pharmaceutical preparation containing granulocyte colony stimulating factor
|
US5186931A
(en)
*
|
1986-08-06 |
1993-02-16 |
Ajinomoto Co., Inc. |
Composition and method for supporting bone marrow transplantation
|
WO1988001297A1
(en)
*
|
1986-08-11 |
1988-02-25 |
Cetus Corporation |
Expression of g-csf and muteins thereof
|
JPH0618781B2
(ja)
*
|
1986-10-18 |
1994-03-16 |
中外製薬株式会社 |
感染症治療剤
|
US6238889B1
(en)
*
|
1986-12-16 |
2001-05-29 |
Dsm N.V. |
Molecular cloning and expression of the Pro8 isoform of human IL-3
|
JP2618618B2
(ja)
*
|
1988-03-04 |
1997-06-11 |
協和醗酵工業株式会社 |
抗g−csf誘導体、nd28モノクローナル抗体
|
US5214132A
(en)
*
|
1986-12-23 |
1993-05-25 |
Kyowa Hakko Kogyo Co., Ltd. |
Polypeptide derivatives of human granulocyte colony stimulating factor
|
NO176799C
(no)
|
1986-12-23 |
1995-05-31 |
Kyowa Hakko Kogyo Kk |
DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
|
US5362853A
(en)
*
|
1986-12-23 |
1994-11-08 |
Kyowa Hakko Kogyo Co., Ltd. |
Polypeptide derivatives of human granulocyte colony stimulating factor
|
US5681720A
(en)
*
|
1986-12-23 |
1997-10-28 |
Kyowa Hakko Co., Ltd. |
DNA encoding human granulocyte colony stimulating factor plasmids and host cells comprising same, and methods of expressing the encoded polypeptide
|
US5194592A
(en)
*
|
1986-12-23 |
1993-03-16 |
Kyowa Hakko Kogyo Co. Ltd. |
Monoclonal antibodies to novel polypeptide derivatives of human granulocyte colony stimulating factor
|
US6384194B1
(en)
*
|
1987-12-16 |
2002-05-07 |
Dsm N.V. |
Expression and purification of human interleukin-3 and muteins thereof
|
GB2213821B
(en)
*
|
1987-12-23 |
1992-01-02 |
British Bio Technology |
Synthetic human granulocyte colony stimulating factor gene
|
US5599690A
(en)
*
|
1988-02-01 |
1997-02-04 |
Amgen Inc. |
Control of norleucine incorporation into recombinant proteins
|
CA1329119C
(en)
*
|
1988-03-29 |
1994-05-03 |
Milton David Goldenberg |
Cytotoxic therapy
|
US20030232010A2
(en)
*
|
1988-03-29 |
2003-12-18 |
Immunomedics, Inc. |
Improved cytotoxic therapy
|
WO1989010932A1
(en)
*
|
1988-05-13 |
1989-11-16 |
Amgen Inc. |
Compositions and method for treating or preventing infections in animals
|
US5070013A
(en)
*
|
1988-05-31 |
1991-12-03 |
Schering Corporation |
Immunochemical assay for human granulocyte-macrophage colony stimulating factor
|
US5082774A
(en)
*
|
1988-08-30 |
1992-01-21 |
The General Hospital Corporation |
Recombinant human nerve growth factor
|
US5218092A
(en)
*
|
1988-09-29 |
1993-06-08 |
Kyowa Hakko Kogyo Co., Ltd. |
Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains
|
US5104651A
(en)
*
|
1988-12-16 |
1992-04-14 |
Amgen Inc. |
Stabilized hydrophobic protein formulations of g-csf
|
US20020177688A1
(en)
*
|
1988-12-22 |
2002-11-28 |
Kirin-Amgen, Inc., |
Chemically-modified G-CSF
|
US6166183A
(en)
*
|
1992-11-30 |
2000-12-26 |
Kirin-Amgen, Inc. |
Chemically-modified G-CSF
|
WO1990006952A1
(en)
*
|
1988-12-22 |
1990-06-28 |
Kirin-Amgen, Inc. |
Chemically modified granulocyte colony stimulating factor
|
WO1990012877A1
(en)
*
|
1989-04-19 |
1990-11-01 |
Cetus Corporation |
Multifunctional m-csf proteins and genes encoding therefor
|
US6254861B1
(en)
*
|
1989-05-23 |
2001-07-03 |
Chandra Choudhury |
Hematopoietic growth factor derived from T lymphocytes
|
US5605822A
(en)
*
|
1989-06-15 |
1997-02-25 |
The Regents Of The University Of Michigan |
Methods, compositions and devices for growing human hematopoietic cells
|
US5763266A
(en)
*
|
1989-06-15 |
1998-06-09 |
The Regents Of The University Of Michigan |
Methods, compositions and devices for maintaining and growing human stem and/or hematopoietics cells
|
US5635386A
(en)
|
1989-06-15 |
1997-06-03 |
The Regents Of The University Of Michigan |
Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture
|
DK0477290T3
(da)
*
|
1989-06-15 |
1997-07-21 |
Univ Michigan |
Fremgangsmåder, sammensætninger og indretninger til dyrkning af celler
|
US6203976B1
(en)
|
1989-07-18 |
2001-03-20 |
Osi Pharmaceuticals, Inc. |
Methods of preparing compositions comprising chemicals capable of transcriptional modulation
|
US5776502A
(en)
|
1989-07-18 |
1998-07-07 |
Oncogene Science, Inc. |
Methods of transcriptionally modulating gene expression
|
US5580722A
(en)
*
|
1989-07-18 |
1996-12-03 |
Oncogene Science, Inc. |
Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
|
US5665543A
(en)
*
|
1989-07-18 |
1997-09-09 |
Oncogene Science, Inc. |
Method of discovering chemicals capable of functioning as gene expression modulators
|
EP0447523A4
(en)
*
|
1989-10-10 |
1991-11-27 |
Amgen Inc. |
Compositions and methods for treating or preventing infections in canine and feline animals
|
CA2025181A1
(en)
*
|
1989-10-12 |
1991-04-13 |
William G. Weisburg |
Nucleic acid probes and methods for detecting fungi
|
US20040181044A1
(en)
*
|
1989-10-16 |
2004-09-16 |
Zsebo Krisztina M. |
Method of stimulating growth of epithelial cells by administering stem cell factor
|
US6852313B1
(en)
|
1989-10-16 |
2005-02-08 |
Amgen Inc. |
Method of stimulating growth of melanocyte cells by administering stem cell factor
|
US7144731B2
(en)
|
1989-10-16 |
2006-12-05 |
Amgen Inc. |
SCF antibody compositions and methods of using the same
|
ATE403713T1
(de)
*
|
1989-10-16 |
2008-08-15 |
Amgen Inc |
Stamzellfaktor
|
RU2212411C2
(ru)
*
|
1989-10-16 |
2003-09-20 |
Эмджен Инк. |
Полипептид, обладающий гемопоэтической биологической активностью фактора стволовых клеток (варианты), днк (варианты), экспрессирующий вектор (варианты), фармацевтическая композиция для гемопоэтической терапии, способ получения полипептида и способ его использования (варианты)
|
ZA907921B
(en)
|
1989-10-16 |
1991-08-28 |
Amgen Inc |
Stem cell factor
|
US5132212A
(en)
*
|
1989-11-17 |
1992-07-21 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Scl gene, and a hematopoietic growth and differentiation factor encoded thereby
|
US5214133A
(en)
*
|
1989-11-17 |
1993-05-25 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
SCL: a hematopoietic growth and differentiation factor
|
JPH04218000A
(ja)
*
|
1990-02-13 |
1992-08-07 |
Kirin Amgen Inc |
修飾ポリペプチド
|
US5147799A
(en)
*
|
1990-04-25 |
1992-09-15 |
Isia Bursuker |
Repopulation of macrophages and granulocytes using transforming growth factor-beta
|
GB9107846D0
(en)
*
|
1990-04-30 |
1991-05-29 |
Ici Plc |
Polypeptides
|
US5399345A
(en)
*
|
1990-05-08 |
1995-03-21 |
Boehringer Mannheim, Gmbh |
Muteins of the granulocyte colony stimulating factor
|
US5258367A
(en)
*
|
1990-06-29 |
1993-11-02 |
University Of Florida |
Uteroferrin and rose proteins for stimulating hematopoietic cells
|
IE912365A1
(en)
*
|
1990-07-23 |
1992-01-29 |
Zeneca Ltd |
Continuous release pharmaceutical compositions
|
CA2081104A1
(en)
*
|
1991-02-22 |
1992-08-23 |
Glenn Pierce |
Use of gm-csf and g-csf to promote accelerated wound healing
|
GB2253852B
(en)
*
|
1991-02-26 |
1995-03-22 |
Ici Plc |
Vector for expression of heterologous polypeptide comprising inducible selection system
|
US6565841B1
(en)
|
1991-03-15 |
2003-05-20 |
Amgen, Inc. |
Pulmonary administration of granulocyte colony stimulating factor
|
FR2686899B1
(fr)
*
|
1992-01-31 |
1995-09-01 |
Rhone Poulenc Rorer Sa |
Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
|
US6413509B1
(en)
|
1992-11-24 |
2002-07-02 |
S. Christopher Bauer |
Methods of ex-vivo expansion of hematopoietic cells using interleukin-3 mutant polypeptides with other hematopoietic growth factors
|
US6361977B1
(en)
|
1992-11-24 |
2002-03-26 |
S. Christopher Bauer |
Methods of using multivariant IL-3 hematopoiesis fusion protein
|
US5738849A
(en)
*
|
1992-11-24 |
1998-04-14 |
G. D. Searle & Co. |
Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them
|
US6153183A
(en)
*
|
1992-11-24 |
2000-11-28 |
G. D. Searle & Company |
Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production
|
US6361976B1
(en)
|
1992-11-24 |
2002-03-26 |
S. Christopher Bauer |
Co-administration of interleukin-3 mutant polypeptides with CSF'S for multi-lineage hematopoietic cell production
|
US7091319B1
(en)
|
1992-11-24 |
2006-08-15 |
Bauer S Christopher |
IL-3 variant hematopoiesis fusion protein
|
US6403076B1
(en)
|
1992-11-24 |
2002-06-11 |
S. Christopher Bauer |
Compositions for increasing hematopoiesis with interleukin-3 mutants
|
US5772992A
(en)
*
|
1992-11-24 |
1998-06-30 |
G.D. Searle & Co. |
Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors
|
US6057133A
(en)
*
|
1992-11-24 |
2000-05-02 |
G. D. Searle |
Multivariant human IL-3 fusion proteins and their recombinant production
|
AU2007200247B2
(en)
*
|
1993-01-28 |
2011-03-10 |
Amgen Inc. |
G-CSF analog compositions
|
US5581476A
(en)
*
|
1993-01-28 |
1996-12-03 |
Amgen Inc. |
Computer-based methods and articles of manufacture for preparing G-CSF analogs
|
ATE437942T1
(de)
|
1993-09-15 |
2009-08-15 |
Novartis Vaccines & Diagnostic |
Rekombinante alphavirus-vektoren
|
US5874075A
(en)
*
|
1993-10-06 |
1999-02-23 |
Amgen Inc. |
Stable protein: phospholipid compositions and methods
|
US20050059149A1
(en)
*
|
1993-11-22 |
2005-03-17 |
Bauer S. Christopher |
Methods of ex-vivo expansion of hematopoeitic cells using multivariant IL-3 hematopoiesis chimera proteins
|
CA2139385C
(en)
*
|
1994-02-04 |
2001-12-25 |
Gottfried Alber |
Products containing g-csf and tnf binding protein
|
US5631219A
(en)
*
|
1994-03-08 |
1997-05-20 |
Somatogen, Inc. |
Method of stimulating hematopoiesis with hemoglobin
|
US6242417B1
(en)
|
1994-03-08 |
2001-06-05 |
Somatogen, Inc. |
Stabilized compositions containing hemoglobin
|
DK0690127T3
(da)
*
|
1994-03-31 |
1999-05-03 |
Amgen Inc |
Sammensætninger og fremgangsmåder til stimulering af megakaryocytvækst og -differentiering
|
US5795569A
(en)
*
|
1994-03-31 |
1998-08-18 |
Amgen Inc. |
Mono-pegylated proteins that stimulate megakaryocyte growth and differentiation
|
US5536495A
(en)
*
|
1994-04-15 |
1996-07-16 |
Foster; Preston F. |
Use of G-CSF to reduce acute rejection
|
US20030053982A1
(en)
*
|
1994-09-26 |
2003-03-20 |
Kinstler Olaf B. |
N-terminally chemically modified protein compositions and methods
|
US5824784A
(en)
*
|
1994-10-12 |
1998-10-20 |
Amgen Inc. |
N-terminally chemically modified protein compositions and methods
|
US6100070A
(en)
*
|
1995-10-05 |
2000-08-08 |
G. D. Searle & Co. |
G-CSF receptor agonists
|
US6066318A
(en)
*
|
1995-10-05 |
2000-05-23 |
G.D. Searle & Co. |
Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
|
EP1997900A3
(en)
|
1996-04-05 |
2010-10-06 |
Novartis Vaccines and Diagnostics, Inc. |
Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
|
WO1998012332A1
(en)
|
1996-09-17 |
1998-03-26 |
Chiron Corporation |
Compositions and methods for treating intracellular diseases
|
US6162426A
(en)
*
|
1997-05-05 |
2000-12-19 |
La Gamma; Edmund F. |
Use of G-CSF to enhance the immune system in neonates
|
US7495087B2
(en)
|
1997-07-14 |
2009-02-24 |
Bolder Biotechnology, Inc. |
Cysteine muteins in the C-D loop of human interleukin-11
|
US7153943B2
(en)
|
1997-07-14 |
2006-12-26 |
Bolder Biotechnology, Inc. |
Derivatives of growth hormone and related proteins, and methods of use thereof
|
IL133974A0
(en)
*
|
1997-07-14 |
2001-04-30 |
Bolder Biotechnology Inc |
Derivatives of growth hormone and related proteins
|
US20080076706A1
(en)
|
1997-07-14 |
2008-03-27 |
Bolder Biotechnology, Inc. |
Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof
|
US6753165B1
(en)
*
|
1999-01-14 |
2004-06-22 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
US6017876A
(en)
*
|
1997-08-15 |
2000-01-25 |
Amgen Inc. |
Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
|
JP4891477B2
(ja)
*
|
1997-10-02 |
2012-03-07 |
マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー.ヴェー. |
血管新生及び/または既存細動脈網から側枝動脈及び/または他の動脈の発達の調節に関する方法
|
US20020034819A1
(en)
*
|
1998-02-23 |
2002-03-21 |
Alan K. Smith |
Human lineage committed cell composition with enhanced proliferative potential, biological effector function, or both; methods for obtaining same; and their uses
|
US6541033B1
(en)
|
1998-06-30 |
2003-04-01 |
Amgen Inc. |
Thermosensitive biodegradable hydrogels for sustained delivery of leptin
|
CN1101403C
(zh)
*
|
1998-07-13 |
2003-02-12 |
金磊 |
粒细胞集落刺激因子的制备
|
US6979442B1
(en)
|
1998-08-17 |
2005-12-27 |
Pfizer Inc. |
Stabilized protein compositions
|
US5999474A
(en)
|
1998-10-01 |
1999-12-07 |
Monolithic System Tech Inc |
Method and apparatus for complete hiding of the refresh of a semiconductor memory
|
US6420339B1
(en)
|
1998-10-14 |
2002-07-16 |
Amgen Inc. |
Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
|
US6245740B1
(en)
|
1998-12-23 |
2001-06-12 |
Amgen Inc. |
Polyol:oil suspensions for the sustained release of proteins
|
US6451346B1
(en)
*
|
1998-12-23 |
2002-09-17 |
Amgen Inc |
Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
EP1141313A2
(en)
|
1998-12-31 |
2001-10-10 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
US7208473B2
(en)
*
|
1999-01-06 |
2007-04-24 |
Xencor, Inc. |
Nucleic acids and protein variants of hG-CSF with granulopoietic activity
|
CA2357811A1
(en)
|
1999-01-06 |
2000-07-13 |
Xencor, Inc. |
Nucleic acids and proteins corresponding to mutants of g-csf with granulopoietic activity
|
US8288126B2
(en)
|
1999-01-14 |
2012-10-16 |
Bolder Biotechnology, Inc. |
Methods for making proteins containing free cysteine residues
|
ATE420665T1
(de)
|
1999-01-19 |
2009-01-15 |
Molecular Insight Pharm Inc |
Konjugate des granulozyten-kolonie stimulierenden faktors zur gezielten bildgebung von infektionen und entzündungen
|
EA200400067A1
(ru)
*
|
1999-01-29 |
2004-04-29 |
Эмджен Инк. |
Конъюгаты гксф
|
US6365583B1
(en)
|
1999-02-02 |
2002-04-02 |
Anormed, Inc. |
Methods to enhance white blood cell count
|
KR100356140B1
(ko)
*
|
1999-07-08 |
2002-10-19 |
한미약품공업 주식회사 |
인간 과립구 콜로니 자극인자 변이체 및 이의 생산 방법
|
US8106098B2
(en)
*
|
1999-08-09 |
2012-01-31 |
The General Hospital Corporation |
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
|
JP5099951B2
(ja)
*
|
1999-11-12 |
2012-12-19 |
バクスター・インターナショナル・インコーポレイテッド |
副作用が減少されたヘモグロビン組成物
|
US6831158B2
(en)
*
|
2000-01-10 |
2004-12-14 |
Maxygen Holdings Ltd. |
G-CSF conjugates
|
US6555660B2
(en)
*
|
2000-01-10 |
2003-04-29 |
Maxygen Holdings Ltd. |
G-CSF conjugates
|
AR027509A1
(es)
|
2000-01-10 |
2003-04-02 |
Maxygen Aps |
Conjugados g-csf
|
US6646110B2
(en)
*
|
2000-01-10 |
2003-11-11 |
Maxygen Holdings Ltd. |
G-CSF polypeptides and conjugates
|
DE60103940T2
(de)
|
2000-02-29 |
2005-07-28 |
Pfizer Products Inc., Groton |
Stabilisierter Granulozyten-Kolonie-stimulierender Faktor
|
EP1272189A4
(en)
*
|
2000-03-31 |
2004-01-14 |
Celgene Corp |
INHIBITION OF CYCLOOXYGENASE-2 ACTIVITY
|
JP2003530838A
(ja)
|
2000-04-12 |
2003-10-21 |
ヒューマン ゲノム サイエンシズ インコーポレイテッド |
アルブミン融合タンパク質
|
US8435939B2
(en)
|
2000-09-05 |
2013-05-07 |
Biokine Therapeutics Ltd. |
Polypeptide anti-HIV agent containing the same
|
AU9096001A
(en)
|
2000-09-08 |
2002-03-22 |
Amgen Inc |
G-csf analog compositions and methods
|
US20020150979A1
(en)
*
|
2000-10-04 |
2002-10-17 |
Naokazu Naitou |
Process for producing a protein
|
NZ526683A
(en)
*
|
2000-11-30 |
2008-03-28 |
Childrens Medical Center |
Synthesis of 4-amino-thalidomide and its enantiomers that are suitable for inhibiting angiogenesis
|
EP1229045A1
(en)
|
2001-02-01 |
2002-08-07 |
Institut Curie |
Universal carrier for targeting molecules to Gb3 receptor expressing cells
|
ES2309167T3
(es)
|
2001-02-19 |
2008-12-16 |
Merck Patent Gmbh |
Metodo para identificar epitotes de celulas t y metodo para preparar moleculas con inmunogenicidad reducida.
|
FR2820979B1
(fr)
|
2001-02-22 |
2004-03-12 |
Didier Pourquier |
Nouvelle application therapeutique du g-csf
|
US6956023B1
(en)
|
2001-04-19 |
2005-10-18 |
University Of Florida |
Materials and methods for providing nutrition to neonates
|
CA2452015C
(en)
|
2001-07-05 |
2012-07-03 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
US20030198621A1
(en)
|
2001-07-05 |
2003-10-23 |
Megede Jan Zur |
Polynucleotides encoding antigenic HIV type B and/or type C polypeptides, polypeptides and uses thereof
|
DE60236522D1
(de)
|
2001-07-11 |
2010-07-08 |
Maxygen Inc |
G-csf konjugate
|
EP1411918B1
(en)
*
|
2001-07-31 |
2011-12-28 |
Genzyme Global S.à.r.l. |
Methods to mobilize progenitor/stem cells
|
US7169750B2
(en)
*
|
2001-07-31 |
2007-01-30 |
Anormed, Inc. |
Methods to mobilize progenitor/stem cells
|
US20030104996A1
(en)
*
|
2001-08-30 |
2003-06-05 |
Tiansheng Li |
L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
|
EP2305311A3
(en)
|
2001-10-10 |
2011-07-20 |
BioGeneriX AG |
Glycoconjugation of peptides
|
ES2516041T3
(es)
|
2001-10-10 |
2014-10-30 |
Ratiopharm Gmbh |
Remodelación y glicoconjugación de la hormona del crecimiento humano (hGH)
|
SI21102A
(sl)
|
2001-12-19 |
2003-06-30 |
LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. |
Postopek za izolacijo biološko aktivnega granulocitne kolonije stimulirajočega dejavnika
|
CA2471363C
(en)
|
2001-12-21 |
2014-02-11 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
KR20030062854A
(ko)
*
|
2002-01-21 |
2003-07-28 |
주식회사 엘지생명과학 |
분비형 벡터를 이용한 효모에서의 재조합 단백질의 제조방법
|
AU2003210052A1
(en)
*
|
2002-03-20 |
2003-09-29 |
Biopolymed Inc. |
Preparation of g-csf stoichiometrically conjugated with biocompatible polymers at cystein residue
|
US20030191056A1
(en)
|
2002-04-04 |
2003-10-09 |
Kenneth Walker |
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
|
EP1497437A4
(en)
|
2002-05-01 |
2005-11-16 |
Cell Genesys Inc |
LENTIVIRAL VECTOR PARTICLES RESISTANT TO THE INACTIVATION OF A COMPLEMENT
|
US20100129363A1
(en)
*
|
2002-05-17 |
2010-05-27 |
Zeldis Jerome B |
Methods and compositions using pde4 inhibitors for the treatment and management of cancers
|
USRE48890E1
(en)
|
2002-05-17 |
2022-01-11 |
Celgene Corporation |
Methods for treating multiple myeloma with 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione after stem cell transplantation
|
US7323479B2
(en)
|
2002-05-17 |
2008-01-29 |
Celgene Corporation |
Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
|
CN103393681B
(zh)
|
2002-05-17 |
2017-04-12 |
细胞基因公司 |
用于治疗和控制多发性骨髓瘤的方法及组合物
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
NZ570777A
(en)
|
2002-05-17 |
2009-04-30 |
Celgene Corp |
Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
|
US7393862B2
(en)
|
2002-05-17 |
2008-07-01 |
Celgene Corporation |
Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
|
US7081443B2
(en)
|
2002-05-21 |
2006-07-25 |
Korea Advanced Institutes Of Science And Technology (Kaist) |
Chimeric comp-ang1 molecule
|
WO2004001056A1
(en)
*
|
2002-06-24 |
2003-12-31 |
Dr. Reddy's Laboratories Ltd. |
Process for preparing g-csf
|
SI21273A
(sl)
*
|
2002-07-31 |
2004-02-29 |
LEK farmacevtska dru�ba d.d. |
Priprava inkluzijskih teles z visokim deležem pravilno zvitega prekurzorja heterolognega proteina
|
US7423007B2
(en)
|
2002-08-27 |
2008-09-09 |
Biokine Therapeutics Ltd. |
Cxcr4 antagonist and use thereof
|
DE60332358D1
(de)
*
|
2002-09-09 |
2010-06-10 |
Hanall Pharmaceutical Co Ltd |
Protease-resistente modifizierte interferon alpha polypeptide
|
EP1900369A1
(en)
|
2002-10-15 |
2008-03-19 |
Celgene Corporation |
Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of myelodysplastic syndromes
|
US7189740B2
(en)
*
|
2002-10-15 |
2007-03-13 |
Celgene Corporation |
Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
|
US11116782B2
(en)
|
2002-10-15 |
2021-09-14 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
US8404717B2
(en)
*
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes using lenalidomide
|
US8404716B2
(en)
|
2002-10-15 |
2013-03-26 |
Celgene Corporation |
Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
|
NZ539534A
(en)
*
|
2002-10-15 |
2008-06-30 |
Celgene Corp |
Selective cytokine inhibitory drugs for treating myelodysplastic syndrome
|
AU2003290652B2
(en)
|
2002-11-06 |
2008-06-19 |
Celgene Corporation |
Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
|
EP1571910A4
(en)
*
|
2002-11-26 |
2009-10-28 |
Anthrogenesis Corp |
CYTOTHERAPEUTIC AGENTS, CYTOTHERAPEUTIC UNITS AND METHODS OF TREATMENT IN WHICH THEY INTERVENE
|
US7695723B2
(en)
|
2002-12-31 |
2010-04-13 |
Sygnis Bioscience Gmbh & Co. Kg |
Methods of treating neurological conditions with hematopoietic growth factors
|
US7785601B2
(en)
*
|
2002-12-31 |
2010-08-31 |
Sygnis Bioscience Gmbh & Co. Kg |
Methods of treating neurological conditions with hematopoietic growth factors
|
RU2353385C2
(ru)
*
|
2002-12-31 |
2009-04-27 |
Зигнис Байосайенс Гмбх Унд Ко. Кг |
Способы лечения неврологических состояний с применением гематопоэтических факторов роста
|
NZ542127A
(en)
*
|
2003-02-13 |
2008-04-30 |
Anthrogenesis Corp |
Use of umbilical cord blood to treat individuals having a disease, disorder or condition
|
ES2436606T3
(es)
|
2003-03-12 |
2014-01-03 |
Celgene Corporation |
Compuestos de 7-amido-isoindolilo y sus usos farmacéuticos
|
AU2004229465B2
(en)
*
|
2003-04-09 |
2010-04-29 |
The United States Of America Department Of Veterans Affairs |
Compositions and methods related to production of erythropoietin
|
EP1615945B1
(en)
|
2003-04-09 |
2011-09-28 |
BioGeneriX AG |
Glycopegylation methods and proteins/peptides produced by the methods
|
MXPA05011353A
(es)
|
2003-04-22 |
2005-11-28 |
Anormed Inc |
Compuestos heterociclicos que se unen al receptor de quimiocina con eficacia mejorada.
|
US7501518B2
(en)
*
|
2003-04-22 |
2009-03-10 |
Genzyme Corporation |
Methods of making 2,6-diaryl piperidine derivatives
|
CA2536152A1
(en)
*
|
2003-08-22 |
2005-03-03 |
The Council Of The Queensland Institute Of Medical Research |
G-csf derivative for inducing immunological tolerance
|
UA83504C2
(en)
|
2003-09-04 |
2008-07-25 |
Селджин Корпорейшн |
Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
US7220407B2
(en)
*
|
2003-10-27 |
2007-05-22 |
Amgen Inc. |
G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction
|
OA13284A
(en)
*
|
2003-11-06 |
2007-01-31 |
Corporation Celgene |
Methods and compositions using thalidomide for thetreatment and management of cancers and other dis eases.
|
CN101966183A
(zh)
*
|
2003-12-02 |
2011-02-09 |
细胞基因公司 |
用于治疗和控制血红蛋白病和贫血病的方法和组合物
|
WO2005067889A1
(en)
|
2003-12-30 |
2005-07-28 |
Durect Corporation |
Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of active agents, preferably a gnrh
|
JP4889505B2
(ja)
|
2004-02-02 |
2012-03-07 |
アンブレツクス・インコーポレイテツド |
被修飾されたヒト成長ホルモンポリペプチドおよびこれらの使用
|
SE0400942D0
(sv)
*
|
2004-04-08 |
2004-04-08 |
Henrik Arnberg |
Composition and method
|
CN1968695A
(zh)
*
|
2004-04-14 |
2007-05-23 |
细胞基因公司 |
含有用于治疗和控制骨髓发育不良综合征的免疫调节化合物的组合物和使用方法
|
CN1972686A
(zh)
*
|
2004-04-14 |
2007-05-30 |
细胞基因公司 |
选择性细胞因子抑制药在髓发育不良综合征中的用途
|
EP1586334A1
(en)
*
|
2004-04-15 |
2005-10-19 |
TRASTEC scpa |
G-CSF conjugates with peg
|
WO2009100255A2
(en)
|
2008-02-08 |
2009-08-13 |
Ambrx, Inc. |
Modified leptin polypeptides and their uses
|
EP1789074A4
(en)
*
|
2004-08-09 |
2009-08-12 |
Alios Biopharma Inc |
PROTEASE-RESISTANT HYPERGLYCOSYL SYNTHETIC POLYPEPTIDE VARIANTS, ORAL FORMULATIONS AND METHODS OF USING THE SAME
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
WO2006020891A2
(en)
*
|
2004-08-13 |
2006-02-23 |
Anormed Inc. |
Chemokine combinations to mobilize progenitor/stem cells
|
AU2005282449B2
(en)
|
2004-09-07 |
2011-07-14 |
Velico Medical, Inc. |
Apparatus for prolonging survival of platelets
|
EP2457578B1
(en)
|
2004-09-28 |
2015-08-19 |
Aprogen, Inc. |
Chimeric molecule comprising angiopoietin-1 and a coiled-coil domain for use in treating penile erectile dysfunction
|
GB0505353D0
(en)
|
2005-03-16 |
2005-04-20 |
Chem Technologies Ltd E |
Treatment process for concrete
|
CN101072585A
(zh)
|
2004-11-01 |
2007-11-14 |
诺华疫苗和诊断公司 |
产生免疫应答的组合方法
|
AU2005306894B2
(en)
|
2004-11-05 |
2011-11-24 |
Northwestern University |
Use of SCF and G-CSF in the treatment of cerebral ischemia and neurological disorders
|
EP1828241A1
(en)
*
|
2004-12-23 |
2007-09-05 |
Laboratoires Serono S.A. |
G-csf polypeptides and uses thereof
|
US9029331B2
(en)
|
2005-01-10 |
2015-05-12 |
Novo Nordisk A/S |
Glycopegylated granulocyte colony stimulating factor
|
NZ556726A
(en)
|
2005-01-25 |
2011-04-29 |
Cell Therapeutics Inc |
Conjugates of biologically active proteins having a modified in vivo half-life
|
US20060270707A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Zeldis Jerome B |
Methods and compositions using 4-[(cyclopropanecarbonylamino)methyl]-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione for the treatment or prevention of cutaneous lupus
|
RU2007149238A
(ru)
*
|
2005-06-01 |
2009-07-20 |
Максиджен Холдингз Лтд. (Ky) |
Пегилированные полипептиды гксф и способы их получения
|
EP1739179A1
(en)
|
2005-06-30 |
2007-01-03 |
Octapharma AG |
Serum-free stable transfection and production of recombinant human proteins in human cell lines
|
DE102005033250A1
(de)
|
2005-07-15 |
2007-01-18 |
Bioceuticals Arzneimittel Ag |
Verfahren zur Reinigung von G-CSF
|
KR100735784B1
(ko)
*
|
2005-07-20 |
2007-07-06 |
재단법인 목암생명공학연구소 |
인간 과립구콜로니자극인자 변이체 및 이의 화학적 접합물
|
BRPI0614257A2
(pt)
*
|
2005-08-04 |
2011-03-15 |
Nektar Therapeutics Al Corp |
conjugados de uma porção de g-csf e um polìmero
|
US8580814B2
(en)
*
|
2006-04-03 |
2013-11-12 |
Sunesis Pharmaceuticals, Inc. |
Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
|
US20080138295A1
(en)
*
|
2005-09-12 |
2008-06-12 |
Celgene Coporation |
Bechet's disease using cyclopropyl-N-carboxamide
|
JP5552231B2
(ja)
*
|
2005-10-14 |
2014-07-16 |
ベリコ メディカル インコーポレイティッド |
血小板の生存延長のための組成物および方法
|
US20070155791A1
(en)
*
|
2005-12-29 |
2007-07-05 |
Zeldis Jerome B |
Methods for treating cutaneous lupus using aminoisoindoline compounds
|
JP2009527552A
(ja)
*
|
2006-02-24 |
2009-07-30 |
ジェンザイム・コーポレーション |
血流の増加および組織再生の促進またはそのいずれかのための方法
|
DE102006009437A1
(de)
|
2006-03-01 |
2007-09-13 |
Bioceuticals Arzneimittel Ag |
G-CSF-Flüssigformulierung
|
WO2007102814A2
(en)
*
|
2006-03-07 |
2007-09-13 |
Regenetech, Inc. |
Recombinant mammalian molecules and method for production thereof
|
GB0605684D0
(en)
*
|
2006-03-21 |
2006-05-03 |
Sicor Biotech Uab |
Method For Purifying Granulocyte-Colony Stimulating Factor
|
US20100196336A1
(en)
|
2006-05-23 |
2010-08-05 |
Dongsu Park |
Modified dendritic cells having enhanced survival and immunogenicity and related compositions and methods
|
KR20090021215A
(ko)
|
2006-06-12 |
2009-02-27 |
선에시스 파마슈티컬스 인코포레이티드 |
암의 치료를 위한 화합물 및 조성물
|
JP2009545601A
(ja)
*
|
2006-08-02 |
2009-12-24 |
サネシス ファーマシューティカルズ, インコーポレイテッド |
(+)−1,4−ジヒドロ−7−[(3s,4s)−3−メトキシ−4−(メチルアミノ)−1−ピロリジニル]−4−オキソ−1−(2−チアゾリル)−1,8−ナフチリジン−3−カルボン酸の組合せ使用
|
CL2007002218A1
(es)
*
|
2006-08-03 |
2008-03-14 |
Celgene Corp Soc Organizada Ba |
Uso de 3-(4-amino-1-oxo-1,3-dihidro-isoindol-2-il)-piperidina 2,6-diona para la preparacion de un medicamento util para el tratamiento de linfoma de celula de capa.
|
MX2009001445A
(es)
*
|
2006-08-07 |
2009-02-18 |
Genzyme Corp |
Terapia de combinacion.
|
US8663651B2
(en)
|
2006-12-21 |
2014-03-04 |
Biokine Therapeutics Ltd. |
T-140 peptide analogs having CXCR4 super-agonist activity for immunomodulation
|
WO2008096370A2
(en)
*
|
2007-02-05 |
2008-08-14 |
Natco Pharma Limited |
An efficient and novel purification method of recombinant hg-csf
|
EP2076533B1
(en)
*
|
2007-05-02 |
2014-10-08 |
Ambrx, Inc. |
Modified interferon beta polypeptides and their uses
|
CN101801942B
(zh)
*
|
2007-07-17 |
2013-03-27 |
美国艾森生物科学公司 |
杂环化合物和作为抗癌剂的用途
|
US7893045B2
(en)
*
|
2007-08-07 |
2011-02-22 |
Celgene Corporation |
Methods for treating lymphomas in certain patient populations and screening patients for said therapy
|
WO2009023566A2
(en)
|
2007-08-09 |
2009-02-19 |
Genzyme Corporation |
Method of treating autoimmune disease with mesenchymal stem cells
|
ES2524454T3
(es)
|
2007-08-27 |
2014-12-09 |
Ratiopharm Gmbh |
Formulación líquida de G-CSF
|
DE202008017456U1
(de)
|
2007-08-27 |
2009-08-27 |
Biogenerix Ag |
Flüssig-Formulierung von G-CSF-Konjugaten
|
US8758761B2
(en)
*
|
2007-09-30 |
2014-06-24 |
University Of Florida Research Foundation, Inc. |
Combination therapies for treating type 1 diabetes
|
KR100921226B1
(ko)
|
2007-10-04 |
2009-10-12 |
학교법인 선목학원 |
사람 혈액의 과립구집락자극인자(hG-CSF) 유전자를 내장하는 레트로바이러스 발현벡터 및 이에 의해 형질전환된 가금
|
EP2214824A4
(en)
*
|
2007-11-28 |
2015-08-19 |
Smart Tube Inc |
DEVICES, SYSTEMS AND METHODS FOR DETECTING, STIMULATING, STABILIZING AND ANALYZING A BIOLOGICAL SAMPLE
|
US20110008371A1
(en)
|
2007-12-10 |
2011-01-13 |
Sunesis Pharmaceuticals, Inc |
Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
|
WO2009134396A2
(en)
*
|
2008-04-30 |
2009-11-05 |
Neutron Row |
Methods of using corticotropin-releasing factor for the treatment of cancer
|
PL2299984T3
(pl)
|
2008-05-15 |
2019-07-31 |
Celgene Corporation |
Doustne formulacje analogów cytydyny i sposoby ich zastosowania
|
JP5680534B2
(ja)
|
2008-07-23 |
2015-03-04 |
イーライ リリー アンド カンパニー |
修飾されているウシg−csfポリペプチドおよびそれらの使用
|
WO2010092571A2
(en)
|
2009-02-11 |
2010-08-19 |
Yeda Research And Development Co. Ltd. |
Short beta-defensin-derived peptides
|
CN102448472A
(zh)
|
2009-05-25 |
2012-05-09 |
国立大学法人东京工业大学 |
包含与中枢神经细胞的增殖和分化相关的核因子的药物组合物
|
ES2462517T3
(es)
|
2009-06-14 |
2014-05-23 |
Biokine Therapeutics Ltd. |
Terapia con péptidos para aumentar los niveles de plaquetas
|
BRPI1011940B8
(pt)
|
2009-06-22 |
2021-08-03 |
Amgen Inc |
método de redobramento de uma proteína expressa em um sistema de expressão de não mamífero
|
WO2010149357A2
(en)
|
2009-06-24 |
2010-12-29 |
Stephen Evans-Freke |
Methods of using corticotropin-releasing factor for the treatment of cancer
|
EP2445924B2
(en)
|
2009-06-25 |
2023-12-13 |
Amgen Inc. |
Capture purification processes for proteins expressed in a non-mammalian system
|
WO2011056566A2
(en)
|
2009-10-26 |
2011-05-12 |
Sunesis Pharmaceuticals, Inc. |
Compounds and methods for treatment of cancer
|
US20110129858A1
(en)
*
|
2009-11-27 |
2011-06-02 |
Changhua Christian Hospital |
Prognosis Biomarker for Evaluating the Cure Level of Stroke Patient and a Method thereof
|
EA201290541A1
(ru)
|
2009-12-21 |
2013-05-30 |
Амбркс, Инк. |
Модифицированные бычьи соматотропиновые полипептиды и их применение
|
SI2341061T1
(sl)
|
2009-12-31 |
2013-12-31 |
Arven Ilac Sanayi Ve Ticaret A.S. |
Nov postopek za pripravo G-CSF-ja (granulocitne kolonije stimulirajočega faktorja)
|
CN102822173A
(zh)
|
2010-02-19 |
2012-12-12 |
美国艾森生物科学公司 |
杂环化合物和作为抗癌剂的用途
|
WO2011109556A2
(en)
*
|
2010-03-04 |
2011-09-09 |
Pfenex Inc. |
Method for producing soluble recombinant interferon protein without denaturing
|
KR20130038838A
(ko)
*
|
2010-03-12 |
2013-04-18 |
셀진 코포레이션 |
레날리도미드, 및 예측 인자로서 유전자 및 단백질 바이오마커를 사용한 비호지킨 림프종의 치료 방법
|
WO2011123570A2
(en)
|
2010-04-01 |
2011-10-06 |
Pfenex Inc. |
Methods for g-csf production in a pseudomonas host cell
|
US8822663B2
(en)
*
|
2010-08-06 |
2014-09-02 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
AR083006A1
(es)
|
2010-09-23 |
2013-01-23 |
Lilly Co Eli |
Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
|
ES2630031T3
(es)
|
2010-09-28 |
2017-08-17 |
Aegerion Pharmaceuticals, Inc. |
Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
|
WO2012078492A1
(en)
|
2010-12-06 |
2012-06-14 |
Celgene Corporation |
A combination therapy with lenalidomide and a cdk inhibitor for treating multiple myeloma
|
JP2014503597A
(ja)
|
2011-01-31 |
2014-02-13 |
セルジーン コーポレイション |
シチジンアナログの医薬組成物及びその使用方法
|
BR112013023277A2
(pt)
|
2011-03-11 |
2017-06-27 |
Celgene Corp |
métodos de tratamento de câncer usando 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidibna-2,6-diona
|
CA2829570C
(en)
|
2011-03-11 |
2019-05-07 |
Celgene Corporation |
Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
|
CN103688176A
(zh)
|
2011-04-29 |
2014-03-26 |
细胞基因公司 |
利用cereblon作为预报因子治疗癌和炎性疾病的方法
|
US9320777B2
(en)
|
2011-05-13 |
2016-04-26 |
Bolder Biotechnology, Inc. |
Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure
|
US10350139B2
(en)
|
2011-10-25 |
2019-07-16 |
Corning Incorporated |
Pharmaceutical glass packaging assuring pharmaceutical sterility
|
US9474689B2
(en)
|
2011-10-25 |
2016-10-25 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9125884B2
(en)
|
2011-11-01 |
2015-09-08 |
Celgene Corporation |
Methods for treating cancers using oral formulations of cytidine analogs
|
US8889630B2
(en)
|
2011-12-23 |
2014-11-18 |
Carlos Lopez |
Method for hair regrowth using Granulocyte-Colony Stimulating Factor
|
HUP1200171A1
(hu)
|
2012-03-19 |
2013-09-30 |
Richter Gedeon Nyrt |
Módszerek polipeptidek elõállítására
|
HUP1200172A2
(en)
|
2012-03-19 |
2013-10-28 |
Richter Gedeon Nyrt |
Methods for refolding g-csf from inclusion bodies
|
WO2013155347A1
(en)
|
2012-04-11 |
2013-10-17 |
Izumi Raquel |
Bruton's tyrosine kinase inhibitors for hematopoietic mobilization
|
US9439942B2
(en)
|
2012-04-24 |
2016-09-13 |
Biokine Therapeutics Ltd. |
Peptides and use thereof in the treatment of large cell lung cancer
|
CA3136093A1
(en)
|
2012-06-29 |
2014-01-03 |
Celgene Corporation |
Methods for determining drug efficacy using cereblon-associated proteins
|
EP2870238A4
(en)
|
2012-07-05 |
2016-03-09 |
Ohio State Innovation Foundation |
COMPOSITIONS AND METHODS ASSOCIATED WITH VIRAL VACCINES
|
ES2771324T3
(es)
|
2012-08-03 |
2020-07-06 |
Dana Farber Cancer Inst Inc |
Usos médicos de agentes que modulan la activación de las células inmunitarias y métodos de detección correspondientes
|
TWI723266B
(zh)
|
2012-08-09 |
2021-04-01 |
美商西建公司 |
利用3-(4-((4-(嗎啉基甲基)苄基)氧基)-1-氧異吲哚啉-2-基)六氫吡啶-2,6-二酮治療癌症之方法
|
IN2015DN00885A
(fi)
|
2012-08-09 |
2015-06-12 |
Celgene Corp |
|
US9587281B2
(en)
|
2012-08-14 |
2017-03-07 |
Celgene Corporation |
Cereblon isoforms and their use as biomarkers for therapeutic treatment
|
CN104797256A
(zh)
|
2012-09-10 |
2015-07-22 |
细胞基因公司 |
用于治疗局部晚期乳腺癌的方法
|
WO2014160698A1
(en)
|
2013-03-26 |
2014-10-02 |
Celgene Corporation |
SOLID FORMS COMPRISING 4-AMINO-I-β-D-RIBOFURANOSYL-1,3,5-TRIAZIN-2(1H)-ONE AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF
|
BR112015025252A2
(pt)
|
2013-04-02 |
2017-07-18 |
Celgene Corp |
métodos e composições usando 4-amino-2-(2,6-dioxo-piperidina-3-il)-isoindolina-1,3-diona para tratamento e gestão de cânceres de sistema nervoso central
|
US9707154B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9700486B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9603775B2
(en)
|
2013-04-24 |
2017-03-28 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9717649B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9849066B2
(en)
|
2013-04-24 |
2017-12-26 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9713572B2
(en)
|
2013-04-24 |
2017-07-25 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9839579B2
(en)
|
2013-04-24 |
2017-12-12 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707153B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9700485B2
(en)
|
2013-04-24 |
2017-07-11 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9717648B2
(en)
|
2013-04-24 |
2017-08-01 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
US9707155B2
(en)
|
2013-04-24 |
2017-07-18 |
Corning Incorporated |
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
|
EP3004877A4
(en)
|
2013-06-06 |
2017-04-19 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
|
EP2815749A1
(en)
|
2013-06-20 |
2014-12-24 |
IP Gesellschaft für Management mbH |
Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
WO2015057992A1
(en)
|
2013-10-16 |
2015-04-23 |
Izumi Raquel |
Btk inhibitors for hematopoietic mobilization
|
EP3068891A1
(en)
|
2013-11-13 |
2016-09-21 |
Aequus Biopharma Inc. |
Engineered glycoproteins and uses thereof
|
US20150359810A1
(en)
|
2014-06-17 |
2015-12-17 |
Celgene Corporation |
Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
|
WO2015200795A1
(en)
|
2014-06-27 |
2015-12-30 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
|
US9499514B2
(en)
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
EA201790439A1
(ru)
|
2014-08-22 |
2017-07-31 |
Селджин Корпорейшн |
Способы лечения множественной миеломы с применением иммуномодулирующих соединений в комбинации с антителами
|
EP3070099A1
(en)
|
2015-03-16 |
2016-09-21 |
Arven Ilac Sanayi Ve Ticaret A.S. |
A process for preparing granulocyte colony stimulating factor (g-csf)
|
WO2016167291A1
(ja)
|
2015-04-13 |
2016-10-20 |
国立研究開発法人産業技術総合研究所 |
環状化サイトカイン及びその製法
|
SI3313818T1
(sl)
|
2015-06-26 |
2024-03-29 |
Celgene Corporation |
Postopki zdravljenja Kaposijevega sarkoma ali s KSHV povzročenega limfoma, z uporabo imunomodulatornih spojin in uporabe biomarkerjev
|
KR20210089270A
(ko)
|
2015-07-16 |
2021-07-15 |
바이오카인 테라퓨틱스 리미티드 |
암 치료용 조성물 및 방법
|
US11324816B2
(en)
|
2015-08-31 |
2022-05-10 |
Technovax, Inc. |
Human respiratory syncytial virus (HRSV) virus-like particles (VLPS) based vaccine
|
US11229683B2
(en)
|
2015-09-18 |
2022-01-25 |
Bolder Biotechnology, Inc. |
Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure
|
US11207393B2
(en)
|
2015-10-16 |
2021-12-28 |
President And Fellows Of Harvard College |
Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
|
US10947287B2
(en)
|
2015-10-19 |
2021-03-16 |
Sandoz Ag |
DNA coding sequence for human G-CSF
|
CA2998579A1
(en)
|
2015-10-19 |
2017-04-27 |
Sandoz Ag |
Method for producing a recombinant protein with reduced impurities
|
WO2017106328A1
(en)
|
2015-12-14 |
2017-06-22 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
US11357742B2
(en)
|
2015-12-14 |
2022-06-14 |
X4 Pharmaceuticals, Inc. |
Methods for treating cancer
|
US10610527B2
(en)
|
2015-12-22 |
2020-04-07 |
X4 Pharmaceuticals, Inc. |
Methods for treating immunodeficiency disease
|
US10830762B2
(en)
|
2015-12-28 |
2020-11-10 |
Celgene Corporation |
Compositions and methods for inducing conformational changes in cereblon and other E3 ubiquitin ligases
|
JP7071922B2
(ja)
|
2016-01-08 |
2022-05-19 |
セルジーン コーポレイション |
2-(4-クロロフェニル)-n-((2-(2,6-ジオキソピペリジン-3-イル)-1-オキソイソインドリン-5-イル)メチル)-2,2-ジフルオロアセトアミドの固体形態、ならびにそれらの薬学的組成物及び使用
|
PL3399978T3
(pl)
|
2016-01-08 |
2021-04-06 |
Celgene Corporation |
Związki antyproliferacyjne oraz ich kompozycje farmaceutyczne i zastosowania
|
CA3010797C
(en)
|
2016-01-08 |
2024-01-02 |
Celgene Corporation |
Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
|
ES2830726T3
(es)
|
2016-02-23 |
2021-06-04 |
Biolinerx Ltd |
Método para seleccionar un régimen de tratamiento para la leucemia mieloide aguda (LMA)
|
CA3018332A1
(en)
|
2016-03-21 |
2017-09-28 |
Dana-Farber Cancer Institute, Inc. |
T-cell exhaustion state-specific gene expression regulators and uses thereof
|
PL3436019T3
(pl)
|
2016-04-01 |
2022-01-10 |
Signal Pharmaceuticals, Llc |
(1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahydro-2h-piran-4-ylo)amino)- 8-((2,4,6- trichlorofenylo)amino)-9h-puryn-9-ylo)-1-metylocykloheksano- 1-karboksamid i sposoby ich stosowania
|
NZ746554A
(en)
|
2016-04-01 |
2023-03-31 |
Signal Pharm Llc |
Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
|
JP2019510785A
(ja)
|
2016-04-08 |
2019-04-18 |
エックス4 ファーマシューティカルズ, インコーポレイテッド |
癌を処置する方法
|
JP7250520B2
(ja)
|
2016-04-13 |
2023-04-03 |
ヤンセン ファーマシューティカルズ,インコーポレーテッド |
組換えアルテリウイルスレプリコン系およびその使用
|
EP3472129A4
(en)
|
2016-06-21 |
2019-12-04 |
X4 Pharmaceuticals, Inc. |
CXCR4 INHIBITORS AND USES THEREOF
|
CN109562106B
(zh)
|
2016-06-21 |
2023-03-21 |
X4 制药有限公司 |
Cxcr4抑制剂及其用途
|
CA3027495A1
(en)
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
WO2018013693A1
(en)
|
2016-07-13 |
2018-01-18 |
Celgene Corporation |
Solid dispersions and cocrystals comprising 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione compositions and methods of use thereof
|
WO2018013689A1
(en)
|
2016-07-13 |
2018-01-18 |
Celgene Corporation |
Solid dispersions and solid forms comprising 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, method of preparation and use thereof
|
JP7382230B2
(ja)
|
2016-10-17 |
2023-11-16 |
ヤンセン ファーマシューティカルズ,インコーポレーテッド |
組み換えウイルスレプリコン系及びその使用
|
KR102655641B1
(ko)
|
2016-12-05 |
2024-04-05 |
얀센 파마슈티칼즈, 인코포레이티드 |
유전자 발현을 향상시키기 위한 조성물 및 방법
|
WO2018165142A1
(en)
|
2017-03-07 |
2018-09-13 |
Celgene Corporation |
Solid forms of 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidine-2,6-dione, and their pharmaceutical compositions and uses
|
MX2019014875A
(es)
|
2017-06-21 |
2021-01-29 |
SHY Therapeutics LLC |
Compuestos que interaccionan con la superfamilia ras para el tratamiento de cancer, enfermedades inflamatorias, rasopatias y enfermedad fibrotica.
|
PL3644999T3
(pl)
|
2017-06-30 |
2023-05-08 |
Celgene Corporation |
Kompozycje i sposoby zastosowania 2-(4-chlorofenylo)-n-((2-(2,6-dioksopiperydyn-3-ylo)-1-oksoizoindolin-5-ylo)metylo)-2,2-difluoroacetamidu
|
CA3078368A1
(en)
|
2017-10-04 |
2019-04-11 |
Celgene Corporation |
Compositions and methods of use of cis-4-[2-{[(3s,4r)-3-fluorooxan-4-yl]amino}-8-(2,4,6-trichloroanilino)-9h-purin-9-yl]-1-methylcyclohexane-1-carboxamide
|
KR20200061363A
(ko)
|
2017-10-04 |
2020-06-02 |
셀진 코포레이션 |
시스-4-[2-{[(3s,4r)-3-플루오로옥산-4-일]아미노}-8-(2,4,6-트리클로로아닐리노)-9h-퓨린-9-일]-1-메틸사이클로헥산-1-카르복스아미드의 제조 공정
|
CN111565736B
(zh)
*
|
2017-10-11 |
2024-03-08 |
礼蓝美国股份有限公司 |
猪g-csf变体和其用途
|
JP2021502345A
(ja)
|
2017-11-06 |
2021-01-28 |
ラプト・セラピューティクス・インコーポレイテッド |
抗がん剤
|
EA202091517A1
(ru)
|
2017-12-19 |
2020-11-03 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Способы и устройство для доставки вакцин против вируса гепатита b (hbv)
|
EA202091516A1
(ru)
|
2017-12-19 |
2020-11-03 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Способы и композиции для индукции иммунного ответа против вируса гепатита b (hbv)
|
EA202091513A1
(ru)
|
2017-12-19 |
2020-09-09 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Вакцины против вируса гепатита b (hbv) и их применение
|
BR112020014525A2
(pt)
|
2018-01-19 |
2020-12-08 |
Janssen Pharmaceuticals, Inc. |
Induzir e intensificar respostas imunes utilizando sistemas de replicon recombinantes
|
US10548889B1
(en)
|
2018-08-31 |
2020-02-04 |
X4 Pharmaceuticals, Inc. |
Compositions of CXCR4 inhibitors and methods of preparation and use
|
WO2020132071A1
(en)
|
2018-12-19 |
2020-06-25 |
Shy Therapeutics. Llc |
Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease
|
WO2020234742A1
(en)
|
2019-05-20 |
2020-11-26 |
Lupin Limited |
Granulocyte colony stimulating factor purification
|
EP4168414A1
(en)
|
2020-06-18 |
2023-04-26 |
Shy Therapeutics LLC |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
TW202406901A
(zh)
|
2022-04-14 |
2024-02-16 |
美商必治妥美雅史谷比公司 |
新穎gspt1化合物以及新穎化合物之使用方法
|
WO2024064646A1
(en)
|
2022-09-20 |
2024-03-28 |
Celgene Corporation |
Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same
|